View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
November 21, 2018

Wize Pharma reports positive results from LO2A trial

Wize Pharma has reported positive top-line results from its Phase II clinical trial evaluating LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh).

Wize Pharma has reported positive top-line results from its Phase II clinical trial evaluating LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh).

The multi-centre, randomised, double-blind, placebo-controlled trial studied the efficacy and safety of LO2A in comparison with placebo.

Patients were randomly distributed in a 1:1 ratio to either the LO2A or placebo treatment group to receive topical eye drops for three months.

The results are based on the analysis of the trial’s primary endpoint, measured by the reduction in Lissamine green conjunctival staining (LGCS) score from baseline to three months.

“We believe the full results from this study will support our clinical development path and provide firm basis for presentation and discussions with the FDA.”

The analysis included 49 fully evaluable patients, using a mixed model with repeated measures (MMRM) and employing all post baseline observations.

It showed statistical significance between the LO2A group and the placebo group, as well as a strong drift towards significance with average reduction in LGCS score in the LO2A and placebo groups respectively.

Full statistical data from the trial is expected to be available once the statistical results and conclusion are available and approved.

Wize Pharma chairman Noam Danenberg said: “We believe the full results from this study will support our clinical development path and provide firm basis for presentation and discussions with the FDA for the approval pathway of LO2A in the US and additional countries.”

CCh affects up to one-third of dry eye patients in the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena